Isatuximab is a CD38-directed cytolytic monoclonal antibody and is indicated in combination with dexamethasone and pomalidomide in the management of patients with multiple myeloma who have been previously treated with at least two prior agents, including a proteasome inhibitor and lenalidomide [3]. This evidence concerns the gene CD38 and AL amyloidosis.